The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Vaccine developments keep dollar down; Aussie and Kiwi strengthen

Mon, 23rd Nov 2020 08:57

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Nov 23 (Reuters) - Progress towards a COVID-19
vaccine rollout lifted riskier currencies on Monday, keeping the
dollar on its downward trend.

AstraZeneca said on Monday that its vaccine could be
around 90% effective. The British drugmaker will prepare
submission of data to authorities around the world that have a
framework for conditional or early approval.

This was the latest in a string of positive vaccine
developments after U.S.-based Moderna Inc said on Nov.
16 its experimental vaccine was 94.5% effective and, a week
earlier, Pfizer Inc and Germany's BioNTech SE
said their vaccine candidate had demonstrated greater than 90%
efficacy that rose to 95% with analysis of full trial data.

In a quiet overnight session, in which price-action was
limited by a holiday in Japan, currency market sentiment was
also lifted by a top U.S. health official saying on Sunday that
vaccinations could start taking place by mid-December.

"Markets are following pandemic news at the moment - vaccine
optimism seems to be supporting risk assets for the time being,"
said Paul Donovan, chief economist at UBS Global Wealth
Management in a note to clients.

The dollar, which dropped 0.4% last week, continued its
downward trend as traders' risk appetite grew. It was down 0.1%
versus a basket of currencies at 92.234 at 0813 GMT.

The dollar also lost out to the yen, with the pair changing
hands at 103.76 at 0820 GMT.

The New Zealand dollar surged to a two-year high after
strong retail sales data, reducing the risk of further policy
easing. It was up 0.4% on the day at 0.6952 by 0822 GMT
.

The Australian dollar - a liquid proxy for risk - was up
0.4% at 0.73285.

The euro edged up, at $1.1868. European Union
leaders will continue to discuss the bloc's 1.8 trillion euro
($2.14 trillion) COVID-19 recovery plan, which has been vetoed
by Poland and Hungary, German Chancellor Angela Merkel said last
week.

Euro zone flash PMI data is due at 0900 GMT, followed by UK
flash PMIs at 0930 GMT and U.S. at 1445 GMT.

ING strategists wrote in a note to clients that the data
would have to be a significant surprise to have an adverse
affect on the euro.

"Assuming the PMIs are not sharply weaker than consensus, we
could see EUR/USD drifting up the 1.1915/20 area," they wrote.

German PMI data showed that the service sector in Europe's
largest economy contracted faster this month after restrictive
measures were introduced to slow the spread of the second wave
of COVID-19.

The yuan slipped due to fresh U.S.-China tensions.

The Trump administration is close to declaring that 89
Chinese aerospace and other companies have military ties,
restricting them from buying a range of U.S. goods and
technology, according to a draft copy of the list seen by
Reuters.

China said it opposed the possible move. The dollar was up
around 0.2% against the offshore yuan at 0826 GMT, at 6.5651
.
($1 = 0.8425 euros)
(Reporting by Elizabeth Howcroft, Editing by William Maclean)

More News
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.